Wenjuan Wu

Wenjuan Wu

Auto-generated profile, based on publicly available information

Wenjuan Wu

Medical Intensive Care Unit, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
LTLili Tang
Lili Tang
MWMeng Wang
Meng Wang
CSChangbing Shen
Changbing Shen
LWLeilei Wen
Leilei Wen
MLMengqing Li
Mengqing Li
FZFusheng Zhou
Fusheng Zhou

27 January 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
YCYan Chen
Yan Chen
JXJianfeng Xie
Jianfeng Xie
WWWenjuan Wu
Wenjuan Wu
SLShusheng Li
Shusheng Li
YHYu Hu
Yu Hu
BDBin Du
Bin Du
Background: The benefits of intravenous immunoglobulin administration are controversial for critically ill COVID-19 patients.Methods: We analyzed retrospectively the effects of immunoglobulin administration for critically ill COVID-19 patients. The primary outcome was 28-day mortality. Inverse probability of treatment weighting (IPTW) with propensity score was used to account for baseline confounders. Cluster analysis was used to perform phenotype analysis.Results: Between January 1 and February 29, 2020, 754 patients with complete data from 19 hospitals were enrolled. Death at 28 days occurred for 408 (54.1%) patients. There were 392 (52.0%) patients who received intravenous immunoglobulin, at 11 (interquartile range (IQR) 8, 16) days after illness onset; 30% of these patients received intravenous immunoglobulin prior to intensive care unit (ICU) admission. By unadjusted analysis, no difference was observed for 28-day mortality between the immunoglobulin and non-immunoglobulin groups. Similar results were found by propensity score matching (n = 506) and by IPTW analysis (n = 731). Also, IPTW analysis did not reveal any significant difference between hyperinflammation and hypoinflammation phenotypes.Conclusion: No significant association was observed for use of intravenous immunoglobulin and decreased mortality of severe COVID-19 patients. Phenotype analysis did not show any survival benefit for patients who received immunoglobulin therapy.

1 September 2019 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
MCMinglong Cai
Minglong Cai
HHHe Huang
He Huang
DRDelin Ran
Delin Ran
XZXiao-dong Zheng
Xiao-dong Zheng
LWLeilei Wen
Leilei Wen
XZXuejun Zhang
Xuejun Zhang